Delivery Order SPE2DB22D2211-SPE2DB25FSGDC
- Not listed
- The Defense Logistics Agency awarded a $5,621.91 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with an ultimate completion date of September 17, 2025. This firm fixed price contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $26,267.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This is a non-set-aside contract with performance completion targeted for August 18, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the federal government's pharmaceutical procurement needs...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $13,150.18 delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pen injectors on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the federal...
- The Defense Logistics Agency awarded a $12,688.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for Zepbound 12.5 mg/0.5 mL pen injections with a completion date of September 16, 2025. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The delivery is to be performed...
- The Defense Logistics Agency awarded a delivery order valued at $2,690.13 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 18, 2025, with completion targeted for August 19, 2025. This competitive, firm fixed-price delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $31,081.37 on September 22, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 23, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $22,877.40 delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with completion targeted for May 28, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $23,996.70 to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This firm fixed-price delivery order, which is classified as a child contract with no set-aside designation, has an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSGDCDelivery Order
The Defense Logistics Agency awarded a $54,734.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), was awarded without a set-aside designation through competitive procedures. Performance will be completed by September 29, 2025, with fulfillment from the company's Conshohocken, Pennsylvania location. Zepbound is a GLP-1 receptor agonist medication approved for weight management, reflecting the federal government's continued investment in pharmaceutical solutions for military and veteran healthcare systems. AmerisourceBergen Drug Corp, headquartered in Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. The company's DLA Pharmaceutical Prime Vendor Global Program contract enables flexible supply of a comprehensive range of medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare operations worldwide. This specific delivery order for Zepbound represents one of numerous pharmaceutical procurements the company executes under its master contract vehicle, demonstrating its capability to fulfill specialized medication requirements for federal health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $54.7k | 9/26/25 |